Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANTEOTECH LTD Capital/Financing Update 2016

Aug 21, 2016

64304_rns_2016-08-21_6e6409e9-ff0a-464b-acb3-509deb7d6557.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [276 x 86] intentionally omitted <==

22 August 2016

Company Announcements Office Australian Securities Exchange Limited Level 6, 20 Bridge Street Sydney NSW 2000

Notice under section 708A of the Corporations Act 2001(Cth)(“Act”)

This notice is given by Anteo Diagnostics Ltd (ABN 75 070 028 625) ( Anteo ) under sections 708A(5)(e) and 708A(6) of the Corporations Act 2001 Cth (the Act ).

On 22 August 2016, Anteo Diagnostics Limited ("the Company") issued 77,963,722 fully paid ordinary shares in accordance with the terms of its convertible securities issued pursuant to the convertible securities subscription agreement with Bergen Global Opportunity Fund, LP, which was announced to the market on 3 March 2016.

Anteo gives notice that:

  1. The Shares were issued without disclosure to investors under Part 6D.2 of the Act;

  2. As at the date of this notice, Anteo has complied with:

    • (a) The provisions of Chapter 2M of the Act as they apply to Anteo; and

    • (b) Section 674 of the Act; and

  3. As at the date of this notice, there is no excluded information referred to in sections 708A(7) and 708A(8) of the Act, which is required to be disclosed by Anteo.

Yours faithfully

==> picture [595 x 139] intentionally omitted <==

Shane Hartwig Company Secretary